Trials / Completed
CompletedNCT02461771
Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD
Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal APL-2 Therapy for Neovascular Age-Related Macular Degeneration (AMD)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Apellis Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to provide initial safety, tolerability and pharmacokinetics information of intravitreal administration of pegcetacoplan in order to support further development into larger Phase II studies for treatment of patients with AMD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pegcetacoplan | On treatment day, subjects will be administered a single 100 μL IVT injection of pegcetacoplan at the dose corresponding to their treatment assignment. |
Timeline
- Start date
- 2015-01-28
- Primary completion
- 2016-03-08
- Completion
- 2016-03-08
- First posted
- 2015-06-03
- Last updated
- 2020-10-06
- Results posted
- 2020-10-06
Locations
4 sites across 2 countries: United States, Australia
Source: ClinicalTrials.gov record NCT02461771. Inclusion in this directory is not an endorsement.